Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Europa
Basilea Pharmaceutica
Nieuws
Basilea Pharmaceutica
BSLN
SWX
: BSLN
| ISIN: CH0011432447
17/05/2024
43,65 CHF
(-1,47%)
(-1,47%)
17/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Dividend
Technische analyse
TA
Toon enkel gratis nieuws
16 mei 2024 ·
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
· Persbericht
3 mei 2024 ·
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
· Persbericht
24 april 2024 ·
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
· Persbericht
9 april 2024 ·
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
· Persbericht
4 april 2024 ·
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
· Persbericht
11 maart 2024 ·
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
· Persbericht
13 februari 2024 ·
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
· Persbericht
19 januari 2024 ·
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
· Persbericht
15 januari 2024 ·
Basilea announces acquisition of preclinical antibiotics program from Spexis
· Persbericht
5 januari 2024 ·
Basilea provides portfolio status update
· Persbericht
20 december 2023 ·
Basilea announces accelerated loan repayment
· Persbericht
11 december 2023 ·
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
· Persbericht
20 november 2023 ·
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
· Persbericht
13 november 2023 ·
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
· Persbericht
31 oktober 2023 ·
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
· Persbericht
19 oktober 2023 ·
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
· Persbericht
17 oktober 2023 ·
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
· Persbericht
2 oktober 2023 ·
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
· Persbericht
28 september 2023 ·
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
· Persbericht
15 augustus 2023 ·
Basilea reports strong revenue and profit growth in first half-year 2023
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe